Insider Cluster (4 insiders) ·Filed Aug 13, 2026

TAK

TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed1mo ago
Insider cluster: 4 insiders, $1.5M total
Actionable Insight • Neutral

Monitor for any upcoming earnings or pipeline catalysts that might explain the coordinated selling, but the dollar amount is immaterial relative to Takeda's size. This cluster is likely a routine pre-planned sale program and does not signal a change in business outlook.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d ⚠ clustered
TAK ▲ +5.00% at T+20d
NEUTRAL call ✓ call won +5.00% · α vs SPY +6.75% · entry $17.39 → $18.26
Next anchor: T+60d in 5w
Latest observation: T+32 +6.81% FF3 residual α
Entry anchored
Aug 12, 2026
via day open
T+1d
+1.38%
call +1.38% · α +1.58%
$17.63
settled 7w ago
T+5d
+4.26%
call +4.26% · α +6.22%
$18.13
settled 6w ago
T+20d
+5.00%
call +5.00% · α +6.75%
$18.26
settled 22d ago
T+60d
—
call — · α —
—
in 5w

Price Chart

Loading chart...

Executive Summary

A cluster of 4 Takeda insiders (including C-suite executives) sold shares on August 10, 2026, totaling $1.47M. The broader context shows 13 insiders sold the same day for ~$9.74M, but this is less than 0.02% of Takeda's $55.2B market cap, making the activity financially trivial. The coordinated same-price sales suggest a pre-planned program rather than opportunistic trading.

Key Financial Metrics

Direction
selling
Total Value
$1.5M
Insiders
4

Key Facts

  • 4 insiders sold shares on 2026-08-10 at $17.10 per share
  • Total value of the cluster filing is $1.47M; cross-filing context reveals 13 insiders sold ~$9.74M on the same day
  • Sales include the CEO, President of R&D, Chief Medical Officer, and other top executives
  • Total sales represent <0.02% of Takeda's $55.2B market cap
  • All trades occurred at the same price, consistent with a single execution or pre-arranged plan

Financial Impact

Total insider sales of $1.47M (filing) or $9.74M (including cross-filing context) are less than 0.02% of market cap — financially immaterial

insider sentiment

Risk Factors

  • No material risk identified from this cluster due to trivial dollar amount relative to market cap

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-TAK-1786586473408
13 reports for TAK
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for TAK — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$18.60 $18.89▲ +1.56%▲ +1.45%$17.86 (−3.98%)
Aug 21, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$18.18 $18.03▼ −0.83%▼ −1.30%$17.86 (−1.76%)
Aug 19, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$18.34 $18.23▼ −0.60%▼ −0.21%$17.86 (−2.62%)
Aug 14, 2026
7w ago
Court Ruling
NEUTRAL ★ 4/10
$17.63 $18.18▲ +3.12%▲ +4.49%$17.86 (+1.30%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$17.39 $18.13▲ +4.26%▲ +6.22%$17.86 (+2.70%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$17.39 $18.13▲ +4.26%▲ +6.22%$17.86 (+2.70%)
Jul 9, 2026
12w ago
6-K
NEUTRAL ★ 2/10
$16.61 $16.73▲ +0.72%▲ +0.85%$17.86 (+7.53%)
Jul 8, 2026
12w ago
6-K
NEUTRAL ★ 2/10
$16.75 $16.39▼ −2.15%▼ −3.01%$17.86 (+6.63%)
Jul 6, 2026
12w ago
3
NEUTRAL ★ 2/10
$16.89 $16.56▼ −1.95%▼ −2.44%$17.86 (+5.74%)
Jun 29, 2026
13w ago
6-K
NEUTRAL ★ 2/10
$15.98 $16.89▲ +5.69%▲ +4.31%$17.86 (+11.76%)
Showing 10 of 13

US Market Status

Market Closed — Opens Mon (65h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 13, 2026